Katja Kaipio
kaanka@utu.fi +358 29 450 4614 +358 50 476 5793 Kiinamyllynkatu 10 Turku |
- A platform for efficient establishment and drug-response profiling of high-grade serous ovarian cancer organoids (2023)
- Developmental Cell
- A Subset of Secreted Proteins in Ascites Can Predict Platinum-Free Interval in Ovarian Cancer (2022)
- Cancers
- Effects of Wee1 inhibitor adavosertib on patient-derived high-grade serous ovarian cancer cells are multiple and independent of homologous recombination status (2022)
- Frontiers in Oncology
- Longitudinal single-cell RNA-seq analysis reveals stress-promoted chemoresistance in metastatic ovarian cancer (2022)
- Science Advances
- Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246-Sensitive Disease Subtype (2022)
- Molecular Cancer Therapeutics
- Co-evolution of matrisome and adaptive adhesion dynamics drives ovarian cancer chemoresistance (2021)
- Nature Communications
- PRISM: Recovering cell type specific expression profiles from individual composite RNA-seq samples (2021)
- Bioinformatics
- Targeting DNA Homologous Repair Proficiency With Concomitant Topoisomerase II and c-Abl Inhibition (2021)
- Frontiers in Oncology
- ALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR-PI3K/aurora kinase inhibitors (2020)
- Journal of Pathology
- Analysis of single-cell RNA-seq data from ovarian cancer samples before and after chemotherapy links stress-related transcriptional profile with chemotherapy resistance (2020)
- bioRxiv
- Melanocortin 3 receptor activation with [D-Trp8]-γ-MSH suppresses inflammation in apolipoprotein E deficient mice (2020)
- European Journal of Pharmacology
- qSNE: quadratic rate t-SNE optimizer with automatic parameter tuning for large datasets (2020)
- Bioinformatics
- Singling out tumor heterogeneity and chemoresistance in high-grade serous ovarian cancer (2020)
- Clinical Cancer Research
- A Functional Homologous Recombination Assay Predicts Primary Chemotherapy Response and Long-Term Survival in Ovarian Cancer Patients (2018)
- Clinical Cancer Research
- Chemical biology approach to phenotypic intratumor heterogeneity as a source of chemotherapy resistance in high-grade serous ovarian cancer (2018)
- Clinical Cancer Research
- Drug sensitivity and resistance testing (DSRT) of clinically important compounds on primary ovarian cancer cell lines. (2018)
- Clinical Cancer Research
- High-throughput screening of new potential targets for high-grade serous ovarian cancer treatment (2018)
- Clinical Cancer Research
- Identifying differentially methylated sites in samples with varying tumor purity (2018)
- Bioinformatics
- FHOD1 formin is upregulated in melanomas and modifies proliferation and tumor growth (2017)
- Experimental Cell Research
- Hyper-phosphorylation of Sequestosome-1 Distinguishes Resistance to Cisplatin in Patient Derived High Grade Serous Ovarian Cancer Cells (2017)
- Molecular and Cellular Proteomics